In this review:
2019 ESC Guidelines
Chronic coronary syndromes
Diabetes, prediabetes and CV diseases, in collaboration with EASD
Dyslipidaemias
Cardio-oncology
The optimal diagnostic approach to cardiotoxicity
Clinical genetics and precision medicine
Functional annotation of CV disease gene variants of uncertain significance
ODYSSEY trial and clinical outcomes
Insights and lessons from ODYSSEY: which patients benefit most?
Implications of new CV risk reduction indication of PCSK9 inhibitors
Valvular heart disease
Investigating and intervening in low gradient aortic stenosis
Managing mitral regurgitation and reduced LV function
Please login below to download this issue (PDF)